PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor

详细信息    查看全文

• 作者：Gert G. Van den Eynden ; Aymeric Neyret ; Glawdys Fumey ; Marthe Rizk-Rabin ; Peter B. Vermeulen ; Zhor Bouizar ; Jean-Jacques Body ; Luc Y. Dirix
• 关键词：Hypercalcemia of malignancy ; Pancreatic neuroendocrine tumor ; Calcitonin ; Parathyroid-related protein
• 刊名：Bone
• 出版年：2007
• 出版时间：April 2007
• 年：2007
• 卷：40
• 期：4
• 页码：1166-1171
• 全文大小：914 K

文摘

A patient with a primary neuroendocrine tumor of the pancreas, presented with severe hypercalcemia. This hypercalcemia of malignancy (HCM) failed to respond to intensive bisphosphonate treatment and needed continuous enhanced diuresis. Only after successful antitumor therapy did the hypercalcemia subside. Hypercalcemia was associated with increased concentrations of plasma PTHrP, calcitonin and 1,25-(OH)₂D₃. Bone mineral density was markedly increased. We demonstrated the presence of both PTHrP and calcitonin in the tumor at the mRNA and protein level, using RT-PCR, immunohistochemistry and Western blotting.

The high levels of plasma PTHrP and the demonstrated predominant renal mechanism in this case of HCM are suspected to be the cause for its refractoriness to bone resorption inhibitors.

Our findings furthermore suggest that the tumoral production of calcitonin and PTHrP might have contributed to the increased bone mineral storage of calcium and thus probably attenuated the development of frank hypercalcemia.